Drugs / QLS5212
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07467629 | May 2026 → Nov 2027 expected | — | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLS5212 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07467629 ↗ |
| Route | Intravenous | “intravenously administered QLS5212” NCT07467629 ↗ |